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Paragangliomas are rare tumours with a prevalence of 1/10000 to 1/30000. Tumors arising from the paraganglia are
characteristically of low malignant potential. Vertebral metastases are exceedingly rare, and only isolated case
reports have described them. The authors present the clinical course of a 47 years-old female patient with a familial
paraganglioma [PGL] with vertebral metastastization, who underwent an intralesional tumor excision and
corpectomy. Genetic screening demonstrated a new germinal frameshift mutation of the SDHB exon 6
[c.587-591DelC]. After surgery there was normalization of the analytical parameters and imagiologic screening. One
year later she presented a new image in the the pedicle of T11 on the contralateral side of the surgical incision.
She performed 2 treatments with MIBG and 1 cicle of radiotherapy that made the new lesion regress. Currently the
patient does not present any clinical or analytical evidence of new metastasis.
This case outlines the clinical course of a patient with a PGL syndrome for whom a rare vertebral metastasis was
diagnosed. It highlights the importance of identifying patients with germline SDHB mutations, as these patients are
at a high risk of developing malignant disease.
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The paragangliomas/pheochromocytomas are rare
tumours with a prevalence of 1/10000 to 1/30000 [1].
The sympathetic-associated paragangliomas [PGL] arise
from the adrenal medulla or from the sympathetic gan-
glia that extend along the paravertebral axis from the
neck to the abdomen and pelvis. These tumors are usu-
ally functionally active and secrete either catecholamines
or metanephrines. The parasympathetic-associated para-
gangliomas arise in the head and neck region and middle
mediastinum, and are usually nonfunctioning. The term
pheochromocytoma is commonly used for a tumor
located in the adrenal gland [2].
Hereditary cases represent 35% of all pheochromocy-
toma and paraganglioma and are associated with gene
mutations. All cases display an autosomal dominant* Correspondence: manuelrisilva@gmail.com
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distribution, and reproduction in any mediuminheritance pattern with incomplete penetrance and
variable expression [3,4].
Tumors arising from the paraganglia are characteris-
tically of low malignant potential, with only 10% devel-
oping distant spread. The great majority of metastasizing
tumors has evidence of distant spread at diagnosis. Fifty
percent are located at the cervical lymph nodes, and the
others are evenly distributed among bone, lung and liver.
Vertebral metastases are exceedingly rare, and only iso-
lated case reports have described them [5].
The authors present the clinical course of a 47 years-
old female patient with a familial paraganglioma, for
whom an unusual vertebral metastasis was identified
and treated.Case presentation
37 years-old caucasian female, without known diseases
until 1997, when she complains of headaches, restless
feeling, anxiety and palpitations, symptoms that she
attributes to stress. Routine screening showed hyper-
tension that was resistant to medical treatment.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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24 h dosage of vanilmandelic acid [VMA]: 52 mg/24 h
[N: 1.4 – 6.5]; epinephrine: 21 μg/24 h [N 0–20]; nor-
epinephrine: 3161 μg/24 h [N: 23–105]; dopamine:
711 μg/24 h [N: 65–400]; metanephrine: 91 μg/24 h
[N: 52–341]; normetanephrine: 3546 μg/24 h [N 88–
444]. Abdominal CT showed a 5.2 cm mass in the re-
gion of the left adrenal gland, with a corresponding
hyperfixation in the MIBG scintigraphy. She underwent
surgery for exploration and removal of the lesion.
Intraoperatively it was found that the lesion was sepa-
rated from the adrenal gland. This finding together
with the pathologic report of a neoplasia invading the
capsule, not going beyond it, and images of venous in-
vasion made the diagnosis of malignant paraganglioma.
Genetic screening of the patient demonstrated a new
germinal frameshift mutation of the SDHB exon 6
[c.587-591DelC]. There was a family history of aFigure 1 Cintigraphy revealing a solitary hyperfixation on T11.cousin diagnosed at 13 years of age with a dopamine
producing malignant paraganglioma, that died at
30 years of age with wide spread metastasis [cranial
and lumbar].
In the post operative period there was a normalization
of VMA, catecholamines and metanephrines concentra-
tions. On March 2006 routine analyses showed an eleva-
tion of catecholamines. Abdominal MRI showed a
recidiva that was confirmed by MIBG cintylogram. The
patient underwent a new surgical removal of the tumor.
Pathologic report confirmed this to be a local metastasis
of the previous paraganglioma. Once again there was a
normalization of the analytical parameters after surgery
but 12 months after this episode she started complaining
of back pain. Analytical evaluation showed a new eleva-
tion of VMA and catecholamines concentrations. This
time scintigraphy revealed a solitary hyperfixation on
T11 [Figure 1]. CT confirmed a lytic lesion on the body
Figure 2 A well delimited lytic lesion on the left side of T11
body was observed on CT scan. This lesion conditioned a
narrowing of the vertebral canal, with slight compression of the
spinal cord. Arrow indicating the lesion.
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this lesion presented low signal in T1 WI and high signal
in T2 WI and enhanced after gadolinium injection.
These features were suggestive of a probable metastasisFigure 3 On MRI this expansive lesion with low signal in T1 WI and h
enhanced after gadolinium injection. These features suggest the diagno
the lesion.[Figure 3]. The patient was referred to the Spine
Group of our hospital and tumor removal was decided.
She underwent an intralesional tumor excision and
corpectomy, and replacement with an interbody spacer
[Synex, Synthes], autologous graft and a lateral plate
[Vantage, Medtronic] [Figure 4]. The pathologic ana-
lysis of the lesion confirmed a new recidiva of para-
ganglioma. After surgery there was a favorable
evolution with improvement of the clinical symptoms
and normalization of the analytical parameters and
imagiologic screening. The patient was able to resume
work. She was kept under tight medical surveillance
and one year later she presented with new positive
image in the lumbar region, corresponding to a new
image in the pedicle of T11 in the contralateral side of
the surgical incision. She performed 2 treatments with
MIBG [6660 MBq [180 mCi] of MIBG 131] that made
the new lesion diminish and afterwards 1 cicle of
radiotherapy. The patient resumed her daily living with
no limitations, and without any present clinical or ana-
lytical evidence of new metastasis.
The prevalence of catecholamines or metanephrines
secreting tumors in cases of hereditary pheochromocy-
toma and paraganglioma disorders is 10–20% in patients
with von Hippel–Lindau disease, approximately 40% in
patients with multiple endocrine neoplasia type 2A and
2B, and 0.1–5.0% in patients with neurofibromatosis
type 1[6,7].igh signal in T2 WI conditioned left root compression and
sis of a malignant lesion, most probably a metastasis. Arrow indicating
Figure 4 Post Op x-ray after corpectomy, replacement with an
interbody spacer, autologous graft and a lateral plate.
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general population. There aren’t reports stating the real
incidence of paragangliomas, but it is consensual that it
is far bellow the incidence of pheocromocytoma. The
malignant diagnosis is noted according to whether me-
tastasis or invasion exists.
Paragangliomas are commonly bilateral and may be
multicentric. Multicentricity occurs in approximately
10% of tumors. Paragangliomas characteristically have a
slow and unpredictable growth pattern, making it diffi-
cult to determine the natural history of the disease [3].
There are five types of familial paraganglioma [PGL]
syndromes that have been identified with mutations in the
SDH genes that encode subunits of the heterotetrameric
SDH complex. SDH is involved in oxidation of succinate
to fumarate in the Krebs cycle and provides electrons to
the mitochondrial electron transport chain [6].
Investigation has revealed that SDHD mutations [PGL
type 1] are associated with multifocal head and neck para-
gangliomas, whereas SDHB mutations [PGL type 4] are
associated with extra-adrenal disease and malignancy [8,9].Several studies have suggested that patients who are car-
riers of the SDHB mutation [PGL type 4], like the patient
we describe, are more likely to develop extra-adrenal
lesions [abdominal or thoracic] and malignant disease [10].
The WHO defines malignant pheochromocytomas
and paragangliomas as metastatic disease at sites where
chromaffin tissues are not usually present. Metastatic
sites include the lungs, bones, liver, and lymph nodes.
Malignant tumors are typically larger, have a higher mi-
totic count, have extensive local or vascular invasion and
express fewer peptides on immunohistochemical studies
compared with benign tumors [11].
There is little correlation between histologic appear-
ance and malignant potencial. Tumors with significant
atypia and pleomorphism have often behaved in benign
fashion, possibly because they were removed before me-
tastasis. Benign-appearing tumors can behave in aggres-
sive fashion. Several authors have found that the
presence of mitosis in the pathologic specimen correlated
significantly with malignancy [12]. In these series, mitotic
figures were seen in all malignant tumours.
Paragangliomas often exhibit a prolonged time interval
to the development of recurrence or metastasis. Recur-
rence and/or distant metastases have been reported to
occur from 0 to 20 years after diagnosis [3,12].
In the current case the patient presented one local
recidiva and a distant metastasis 9 and 10 years after the
initial diagnosis, respectively. In both situations it was
decided that the patient was eligible for surgical treat-
ment with curative intention because these were always
isolated lesions at the time of diagnosis [13].
The patient underwent a biannual monitoring pro-
gram with physical examination and measurement of
blood pressure and levels of urinary catecholamines and
metanephrines [14]. The fact that the patient presented
only a solitary metastasis was the reason the authors
chose to pursuit a surgical exertion, in an attempt to
perform a curative treatment. It was taken under consid-
eration the fact that metastatic paraganglioma, like
pheochromocytoma, is relatively radioresistant, as com-
pared with lymphoma and breast cancer [13].
The reason to choose a surgical intervention instead
of chemotherapy in the T11 lesion was also based in
the risk of vertebral colapse with the consequent dan-
ger of neurological injury [15]. The exertion of the le-
sion and the replacement by a titanium cage and ilac
gaft was considered to be a better mechanical solution
for the patient, besides the fact that we intended to
have a curative procedure. Nevertheless a new recidiva
was diagnosed one year later. An en bloc excision
would probably have been more appropriate, but at
the time we were not performing this routinely.
Nevertheless, this proved to be at least partially a cor-
rect decision because the patient became assymptomatic
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with no clinical complaints].
One could argue that she should have had chemother-
apy with MIBG imediately after the removal of the verte-
bral metastasis because it was the second recidiva, but it
was decided against that in group reunion. It was taken
in consideration that chemotherapy does not seem to in-
crease the survival in women with metastatic malignant
paraganglioma [16].
When the local vertebral recidiva occurred it was
decided that the patient would undergo MIBG treat-
ment. This option led to a regression in tumour size.
Even in this perpective the surgical procedure was ben-
efic to the patient because the dose of MIBG used is size
dependent.
The patient's direct family was offered genetic screen-
ing, having been diagnosed 5 positive patients, and one
already died of metastatic pheocromocytoma [17].Conclusions
This case outlines the clinical course of a patient with a
PGL type 4 syndrome for whom a rare vertebral metasta-
sis was diagnosed. The case highlights the importance of
offering targeted genetic testing for the SDHB gene
mutations to a patient with multiple, extra-adrenal para-
gangliomas and a family history of malignant paragan-
glioma. It also illustrates the importance of identifying
patients with germline SDHB mutations, as these
patients are at a high risk of developing malignant dis-
ease. On the other hand it also highlights the importance
of a multidisciplinary approach to these patients, as well
as an aggressive attitude towards metastasis, with radical
surgical exertion of the tumor being, whenever it is pos-
sible, the authors’ choice.Consent
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